CoQ10 shifts blood sugar and triglycerides in type 2 diabetes, not cholesterol

People with type 2 diabetes face a higher rate of cardiovascular events, so anything that safely improves their lipid profile, blood sugar control, blood pressure or inflammation deserves scrutiny. Coenzyme Q10, a compound involved in cellular energy production and sold widely as a supplement, has been tested repeatedly in this population, but the trials have pointed in different directions. This review pooled those trials to establish which cardiovascular risk factors CoQ10 actually shifts in prediabetes and type 2 diabetes, and which popular claims do not survive contact with the evidence.

The authors searched PubMed, Web of Science and Scopus from inception to May 2025 for randomised controlled trials of CoQ10 supplementation in people with prediabetes or type 2 diabetes. From 4894 records, 20 eligible trials were included. Outcomes covered lipid and glucose profiles, blood pressure, oxidative stress and inflammation. Results were pooled using random-effects models to account for differences between trials, expressed as weighted mean differences, and the certainty of the evidence was formally graded.

CoQ10 supplementation significantly reduced triglycerides, fasting blood sugar, HbA1c, insulin resistance measured by HOMA-IR, and the inflammatory marker C-reactive protein, while raising HDL cholesterol. The nulls matter just as much: total cholesterol, LDL cholesterol, systolic and diastolic blood pressure, and the oxidative stress marker malondialdehyde did not change significantly. The benefits therefore cluster around glucose control, triglycerides and inflammation rather than the classic cholesterol and blood pressure targets. The authors conclude the supplement may improve several risk factors but call for longer trials with a wider range of doses.

Earlier trials of CoQ10 in diabetes disagreed with each other, which is exactly the situation a pooled analysis exists to resolve. This one suggests a consistent metabolic and anti-inflammatory signal while pushing back on the idea that CoQ10 meaningfully lowers blood pressure or LDL in this population. Open questions include the best dose, how long the benefits take to appear and whether they persist, and the biggest one of all: whether improved markers translate into fewer actual cardiovascular events, which no marker study can answer on its own.

For readers managing blood sugar or prediabetes, this is a reason to see CoQ10 as a supplement with genuine, measurable effects on glucose control, triglycerides and inflammation in trials, not a cure-all. Anyone taking it in the hope of lowering LDL cholesterol or blood pressure should know those outcomes did not improve here. As ever with risk markers, better numbers are encouraging rather than proof of fewer heart attacks.